ASG:CA:CDX-Aurora Spine Corporation (CAD)

COMMON STOCK | Medical Devices | TSX Venture Exchange

Last Closing

USD 0.47

Change

-0.01 (-1.05)%

Market Cap

USD 4.89M

Volume

6.50K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Aurora Spine Corp is in the business of development and commercialization of interspinous fusion systems and devices.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-07 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
TLT:CA Theralase Technologies Inc.

-0.01 (-1.64%)

USD 0.07B
PINK:CA Perimeter Medical Imaging AI I..

+0.03 (+6.02%)

USD 0.05B
MDX:CA MedX Health Corp

N/A

USD 0.02B
NGMD:CA NuGen Medical Devices Inc

N/A

USD 0.02B
VPT:CA VentriPoint Diagnostics Ltd

+0.01 (+4.76%)

USD 0.02B
THRM:CA Therma Bright Inc

-0.01 (-12.50%)

USD 0.01B
EVMT:CA Evome Medical Technologies Inc..

+0.01 (+3.45%)

USD 0.01B
FREQ:CA Frequency Exchange Corp.

N/A

USD 0.01B
CNVI:CA Conavi Medical Corp.

-0.05 (-7.35%)

N/A

ETFs Containing ASG:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (TSX Venture Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 20.51% 100% F 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.51% 100% F 82% B
Trailing 12 Months  
Capital Gain 18.99% 63% D 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.99% 63% D 71% C-
Trailing 5 Years  
Capital Gain 80.77% 80% B- 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 80.77% 80% B- 81% B-
Average Annual (5 Year Horizon)  
Capital Gain 32.68% 75% C 77% C+
Dividend Return 32.68% 75% C 77% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 106.20% 38% F 28% F
Risk Adjusted Return 30.77% 75% C 80% B-
Market Capitalization 4.89M 78% C+ 79% B-

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector